Of the 20 chronic disease patient groups, 55% represent patient interests to drug regulators. The most common form is attending meetings with policymakers/regulators (38%), followed by participation in HTA/reimbursement reviews (25%). 25% advocate for equitable access to healthcare.
55% of respondents from Chronic diseases ‘Regularly’ or ‘Sometimes’ represent patient interests to drug regulators
Patient groups representing each Chronic diseases sub-type
20 patient groups across 3 sub-types
interactions
Activities range from participation in public consultations held by CONITEC [Comissão Nacional de Incorporação de Tecnologias no SUS – National Committee for Health Technology Incorporation] and the ANS [Agência Nacional de Saúde Suplementar – National Supplementary Health Agency].
Desde a participação em Consultas Públicas (CONITEC e ANS) até a efetiva representação através da presença dentro do CNS. Controle e mobilização social, com estratégia, também dialoga com órgãos reguladores.
National rare-disease patient group, Brazil
interactions
POP [Plataforma de Organizaciones de Pacientes – Platform of Patient Organisations] represents patient interests before the regulatory bodies and processes involved in the assessment, pricing, and reimbursement of medicines, through institutional engagement, contributions to public consultations, and the development of position statements aimed at ensuring equity and access.
Sí. La POP representa los intereses de los pacientes ante organismos y procesos regulatorios relacionados con la evaluación, precio y financiación de medicamentos, mediante interlocución institucional, aportaciones a consultas públicas y posicionamientos orientados a garantizar equidad y acceso.
National chronic-disease patient group, Spain
actions & advocacy
Medications that are essential for the provision of quality palliative care are reviewed by us and designated for mandatory availability in local pharmacies.
Medicatie die belangrijk is om goede palliatieve zorg te geven, worden door ons bekeken en ook aangewezen om deze zeker in lokale apotheken te hebben.
Regional chronic-disease patient group, Belgium
actions & advocacy
We have a policy committee and weigh in on public policy issues through education and advocacy.
We have a policy committee and weigh in on public policy issues through education and advocacy.
National chronic-disease patient group, USA
The percentages below highlight how the 8 patient groups interact with regulators and advocate for patient interests. As respondents may be represented in more than one area, percentages may not total 100%.
interactions
7 mentions
3 mentions
2 mentions
1 mention
1 mention
2 mentions
2 mentions
2 mentions
2 mentions
1 mention
1 mention
1 mention
1 mention
actions & advocacy
2 mentions
2 mentions
1 mention
1 mention
1 mention
1 mention
1 mention
1 mention
GET THE REPORT
Our research covers 2,262 patient groups representing 100 countries and 45 therapy areas. The sample report shows you the depth of analysis for a single country or therapy area. To access any other reports, please get in touch.
Visit patient-view.com to gather more information or email: Alex Wyke, alexwyke@patient-view.com
